Neglected Tropical Disease Treatment Global Market Report 2025

The neglected tropical disease treatment market size has grown strongly in recent years. It will grow from $3.36 billion in 2024 to $3.57 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. This historical growth is attributed to a greater government focus on disease elimination programs, expanding public-private partnerships for drug donations, rising pharmaceutical donations from global manufacturers, increasing research into low-cost antiparasitic therapies, and growing investments in vaccine and diagnostic development.

The neglected tropical disease treatment market size is expected to see strong growth in the next few years. It will grow to $4.52 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. Key growth drivers in the forecast period include the expanded use of digital tools for disease monitoring, a growing pipeline of new drugs and vaccines, rising concerns about antimicrobial resistance, enhanced cross-border collaboration for disease control, and the influence of climate change on disease spread. Notable trends expected in the forecast period include the development of localized treatment strategies, affordable vaccine platforms, integration with primary healthcare services, expansion of disease surveillance networks, and innovations in vector control technologies.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the neglected tropical disease treatment market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from one person to another either directly or indirectly. This rise in infectious diseases is primarily attributed to increased global travel, which accelerates the transmission of pathogens across borders. Neglected tropical disease treatment plays a crucial role by offering targeted therapies that help control and eliminate the spread of these diseases. These treatments are particularly beneficial in vulnerable communities, where they improve public health outcomes by reducing disease burden and preventing long-term disabilities. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, a 10.7% rise from 4,380 cases in 2022. This trend highlights how the growing prevalence of infectious diseases is fueling the demand for neglected tropical disease treatments.

Companies in the neglected tropical disease treatment market are emphasizing strategic investments to strengthen research and development, broaden global access, and advance innovative therapies. These investments contribute significantly to market growth by supporting advanced research, encouraging collaborations, and expediting the creation of affordable and effective treatments for underserved populations. For instance, in June 2022, Novartis AG, a pharmaceutical corporation based in Switzerland, committed $250 million toward combating neglected tropical diseases (NTDs) and malaria. This funding aims to make treatments more accessible in low-income regions and to support the development of new therapies for these diseases.

In August 2022, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, and Aurigene Pharmaceutical Services Limited, also based in India, collaborated with the Drugs for Neglected Diseases initiative (DNDi) to develop, manufacture, and commercialize new treatments for neglected tropical diseases. This partnership is intended to speed up the development of affordable and accessible therapies, addressing the unmet medical needs in low- and middle-income countries. The DNDi, headquartered in Switzerland, is a non-profit organization dedicated to developing effective and affordable treatments for neglected tropical diseases.

Major players in the neglected tropical disease treatment market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Eisai Co. Ltd., Shionogi And Co. Ltd., Dr. Reddy`s Laboratories Ltd, Cipla Ltd., Eiken Chemical Company Ltd, LifeArc, Atomwise Inc., and Medicines Development for Global Health Ltd.

Asia Pacific was the largest region in the neglected tropical disease treatment market in 2024. The regions covered in neglected tropical disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neglected tropical disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neglected tropical disease (NTD) treatment refers to medical interventions aimed at controlling, eliminating, or eradicating a group of infectious diseases that predominantly impact impoverished populations in tropical and subtropical areas. The primary objective of these treatments is to reduce the disease burden, prevent disability, and enhance the quality of life within affected communities.

The primary drug classes utilized in treating neglected tropical diseases include anti-parasitic agents, antifungals, antibiotics, and others. Anti-parasitic agents are substances or treatments intended to prevent, kill, or eliminate parasites that infect humans, animals, or plants. These treatments address a range of diseases such as leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. The drugs are administered either orally or parenterally and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. These treatments cater to multiple end users, such as hospitals, specialty clinics, homecare settings, and more.

The neglected tropical disease treatment market research report is one of a series of new reports that provides neglected tropical disease treatment market statistics, including the neglected tropical disease treatment industry's global market size, regional shares, competitors with the neglected tropical disease treatment market share, detailed neglected tropical disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neglected tropical disease treatment market. This neglected tropical disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neglected tropical disease treatment market consists of revenues earned by entities by providing services such as mass drug administration, disease surveillance, diagnostic testing, patient care and management, health education, and vector control programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The neglected tropical disease (NTD) treatment market also includes sales of diagnostic kits, vaccines, insecticides, and medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.